Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur.
| Autor: | Miatech JL; Internal Medicine Residency Program, Baton Rouge General, Baton Rouge, USA., Kantamani D; Internal Medicine, Baton Rouge General, Baton Rouge, USA., Stagg MP; Internal Medicine Residency Program, Baton Rouge General, Baton Rouge, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Oct 30; Vol. 13 (10), pp. e19145. Date of Electronic Publication: 2021 Oct 30 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.19145 |
| Abstrakt: | Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by the production of autoantibodies against coagulation factor VIII (FVIII). AHA is associated with significant morbidity and mortality primarily as a result of bleeding. Although many disorders are associated with the development of these inhibitors, up to 50% of cases remain idiopathic. The approach to therapy involves an initial strategy often to control acute bleeding episodes followed by definitive treatment to eradicate the inhibitor with immunosuppressive agents. We present the case of a 63-year-old Caucasian male hospitalized for severe Covid-19 who developed bleeding due to an acquired FVIII inhibitor that had never been treated definitively. Our case presentation focuses on in-hospital management of this patient's acute bleeding episodes with by-passing agents and recombinant porcine factor VIII. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Miatech et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|